Hormonal Therapy with Megestrol for Liver Cancer
Author Information
Author(s): Villa E, Ferretti I, Grottola A, Buttafoco P, Buono M Grazia Del, Giannini F, Manno M, Bertani H, Dugani A, Manenti F
Primary Institution: Department of Internal Medicine, University of Modena, Italy
Hypothesis
Does megestrol improve survival and tumor growth in patients with hepatocellular carcinoma characterized by variant estrogen receptors?
Conclusion
Megestrol significantly improves survival and slows tumor growth in patients with hepatocellular carcinoma characterized by variant estrogen receptors.
Supporting Evidence
- Megestrol significantly improved survival from a median of 7 months to 18 months.
- Tumor growth was significantly slowed down in megestrol-treated patients.
Takeaway
This study found that a medicine called megestrol helps people with a type of liver cancer live longer and slows down how fast the cancer grows.
Methodology
A prospective, randomized study comparing megestrol to placebo in patients with hepatocellular carcinoma.
Participant Demographics
Patients with hepatocellular carcinoma characterized by variant liver estrogen receptors.
Statistical Information
P-Value
0.0090
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website